Bayer CropScience Ltd (BAYERCROP) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 491198,
    "name": "Bayer CropSci.",
    "stock_name": "Bayer CropSci.",
    "full_name": "Bayer CropScience Ltd",
    "name_url": "stocks-analysis/bayer-cropsci",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "4,495.10",
    "chg": -10.9,
    "chgp": "-0.24%",
    "dir": -1,
    "prev_price": "4,506.00",
    "mcapval": "20,235.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 506285,
    "symbol": "BAYERCROP",
    "ind_name": "Pesticides & Agrochemicals",
    "ind_code": 18,
    "indexname": "",
    "isin": "INE462A01022",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "25.92 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/bayer-cropsci-491198-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Bayer CropSci. Sees Revision in Market Evaluation Amid Challenging Financial Trends",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bayer-cropsci-downgraded-to-sell-by-marketsmojo-amid-weak-financial-and-technical-trends-3733147",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/BayerCropSci_mojoScore_3733147.png",
        "date": "2025-11-27 10:06:18",
        "description": "Bayer CropSci., a small-cap player in the Pesticides & Agrochemicals sector, has experienced a revision in its market evaluation reflecting shifts in its financial and technical outlook. This adjustment follows a period marked by subdued growth and valuation concerns, prompting a reassessment of the company’s standing within its industry."
      },
      {
        "title": "Why is Bayer CropSci. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-bayer-cropsci-fallingrising-3690954",
        "imagepath": "",
        "date": "2025-11-11 22:56:39",
        "description": "As of 11-Nov, Bayer CropScience Ltd is experiencing a decline in its stock price, currently at Rs 4,506.85, which reflects a decrease of 131.1 points or 2.83%. The stock has underperformed its sector by 2.4% today, touching an intraday low of Rs 4,490, which is a drop of 3.19%. Over the past week, the stock has seen a return of -6.81%, and its performance over the last month is also negative at -9.92%. Despite a rise in investor participation, with delivery volume increasing by 90.59% against the 5-day average, the stock is trading below all key moving averages, indicating a bearish trend. Additionally, the company has shown poor long-term growth, with operating profit declining at an annual rate of -3.22% over the last five years, and recent financial results have been flat, contributing to the negative sentiment surrounding the stock.\n\nIn the broader market context, Bayer CropScience's performance contras..."
      },
      {
        "title": "How has been the historical performance of Bayer CropSci.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-bayer-cropsci-3683542",
        "imagepath": "",
        "date": "2025-11-09 22:41:31",
        "description": "Answer:\nThe historical performance of Bayer CropSci. shows a trend of increasing net sales and operating income over the years, with net sales reaching 5,473.40 Cr in March 2025, up from 5,106.20 Cr in March 2024 and 5,139.70 Cr in March 2023. However, operating profit (PBDIT) has seen a decline from 1,035.00 Cr in March 2024 to 809.30 Cr in March 2025. Profit before tax also decreased to 707.40 Cr in March 2025 from 941.40 Cr in March 2024, while profit after tax fell to 568.00 Cr from 740.50 Cr in the same period. The company's total assets increased to 5,236.20 Cr in March 2025, compared to 4,597.10 Cr in March 2024, indicating growth in the asset base. Total liabilities also rose to 5,236.20 Cr from 4,597.10 Cr, reflecting an increase in financial obligations. Cash flow from operating activities decreased significantly to 262.00 Cr in March 2025 from 951.00 Cr in March 2024, contributing to a net cash o..."
      },
      {
        "title": "Are Bayer CropSci. latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-bayer-cropsci-latest-results-good-or-bad-3682447",
        "imagepath": "",
        "date": "2025-11-08 19:19:58",
        "description": "Bayer CropScience's latest financial results for Q2 FY26 highlight significant operational trends, particularly influenced by the seasonal nature of the agrochemicals business. The company reported net sales of ₹1,914.60 crores, reflecting a substantial sequential increase of 82.97% from the previous quarter, driven by heightened demand during the kharif sowing season. Year-on-year, revenue growth stood at 17.36%, indicating resilience in maintaining market share amidst competitive pressures.\n\nNet profit for the same quarter reached ₹278.70 crores, which is a notable increase of 94.50% quarter-on-quarter and 9.64% year-on-year. However, despite these positive profit figures, the operating margin experienced compression, standing at 18.20%. This represents a sequential improvement but a decline compared to the previous year, suggesting challenges in maintaining profitability amidst rising costs or competitiv..."
      },
      {
        "title": "Bayer CropScience Q2 FY26: Strong Quarter Masks Underlying Margin Pressure",
        "link": "https://www.marketsmojo.com/news/result-analysis/bayer-cropscience-q2-fy26-strong-quarter-masks-underlying-margin-pressure-3680609",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/BayerCropScienc_quaterlyResult_3680609.png",
        "date": "2025-11-07 20:02:48",
        "description": "Bayer CropScience Ltd., a prominent player in India's pesticides and agrochemicals sector, reported a net profit of ₹278.70 crores for Q2 FY26 ended June 2025, marking a sequential surge of 94.50% from the preceding quarter's ₹143.30 crores. On a year-on-year basis, the company posted a 9.64% increase from ₹254.20 crores in Q2 FY25. Despite these headline gains, the stock has faced significant headwinds, plunging 30.80% over the past year and currently trading at ₹4,604.15 with a market capitalisation of ₹21,078 crores. The results reveal a company navigating seasonal volatility whilst grappling with margin compression that has persisted across multiple quarters."
      },
      {
        "title": "Why is Bayer CropSci. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-bayer-cropsci-fallingrising-3676981",
        "imagepath": "",
        "date": "2025-11-06 22:45:25",
        "description": "As of 06-Nov, Bayer CropScience Ltd's stock price is currently at Rs 4,754.70, reflecting a decline of Rs 81.4 or 1.68%. The stock has been underperforming, having fallen consecutively for the last four days, resulting in a total decrease of 3.3% over the past week. It has also touched an intraday low of Rs 4,730, which represents a 2.19% drop. In terms of performance against benchmarks, Bayer has seen a significant decline, with a year-to-date return of -14.39% and a one-year return of -28.33%, both of which are considerably worse than the Sensex's positive returns. The stock is trading below all its moving averages, indicating a bearish trend, and there has been a decrease in investor participation, with delivery volume falling by 4.65% compared to the five-day average.\n\nIn the broader market context, Bayer's short-term performance is notably worse than the Sensex, which has seen a decline of only 1.30% o..."
      },
      {
        "title": "Is Bayer CropSci. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-bayer-cropsci-overvalued-or-undervalued-3632870",
        "imagepath": "",
        "date": "2025-10-20 08:06:34",
        "description": "As of 17 October 2025, Bayer CropScience's valuation grade has moved from very expensive to expensive, indicating a slight improvement but still reflecting a high valuation. The company is currently considered overvalued. Key ratios include a PE ratio of 38.24, an EV to EBITDA of 30.04, and a Price to Book Value of 7.95, all of which suggest that the stock is trading at a premium compared to its earnings and book value.\n\nIn comparison to its peers, Bayer CropScience's PE ratio is higher than UPL's 37.91 and BASF India's 47.93, which are both classified as attractive. The PEG ratio stands at 0.00, indicating no growth expectations factored into the price, which is concerning. Recent stock performance shows that Bayer has underperformed against the Sensex, with a year-to-date return of -9.24% compared to the Sensex's 7.44%, reinforcing the notion that the stock may not be a favorable investment at its current..."
      },
      {
        "title": "Is Bayer CropSci. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-bayer-cropsci-overvalued-or-undervalued-3631328",
        "imagepath": "",
        "date": "2025-10-19 08:06:31",
        "description": "As of 17 October 2025, the valuation grade for Bayer CropSci. has moved from very expensive to expensive. The company is currently considered overvalued based on its high valuation ratios, including a PE ratio of 38.24, an EV to EBITDA of 30.04, and a Price to Book Value of 7.95. Compared to peers, Bayer's valuation appears less attractive; for instance, UPL has a PE ratio of 37.91 and an EV to EBITDA of 9.14, while BASF India shows a PE of 47.93 with a lower EV to EBITDA of 28.64.\n\nDespite the company's strong ROCE of 48.74% and ROE of 20.79%, the high valuation ratios suggest that the stock may not provide sufficient upside potential. Additionally, Bayer CropSci. has underperformed against the Sensex, with a year-to-date return of -9.24% compared to the Sensex's 7.44%. This performance further supports the view that the stock is overvalued in its current market context...."
      },
      {
        "title": "Is Bayer CropSci. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-bayer-cropsci-overvalued-or-undervalued-3630470",
        "imagepath": "",
        "date": "2025-10-18 08:06:02",
        "description": "As of 17 October 2025, Bayer CropScience has moved from a valuation grade of very expensive to expensive. The company is currently considered overvalued based on its key financial metrics. The PE ratio stands at 38.24, while the EV to EBITDA ratio is 30.04, and the Price to Book Value is 7.95, all indicating a premium valuation compared to its peers.\n\nIn comparison to its industry peers, Bayer CropScience's valuation appears high, especially when looking at UPL with a PE ratio of 37.91 and BASF India at 47.93. Additionally, the PEG ratio for Bayer is notably low at 0.00, suggesting that growth expectations may not justify the current price. Recent performance has also been underwhelming, with a year-to-date return of -9.24%, significantly lagging behind the Sensex's 7.44% return...."
      }
    ],
    "total": 592,
    "sid": "491198",
    "stock_news_url": "https://www.marketsmojo.com/news/bayer-cropscience-491198"
  },
  "announcements": [
    {
      "details": "Bayer Cropscience Limited has informed the Exchange regarding Notice Published in the Newspaper.",
      "source": "NSE",
      "caption": "Bayer Cropscience Limited - Other General Purpose",
      "datetime": "24-Sep-2019"
    },
    {
      "details": " <table><tr><td>Bayer Cropscience Limited has informed the Exchange regarding Notice Published in the Newspaper. </td></tr></table>",
      "source": "NSE",
      "caption": "Copy of Newspaper Publication",
      "datetime": "23-Sep-2019"
    },
    {
      "details": " <table><tr><td>News Verification : The media had reports that \"Bayer in Talks to buy into Kaveri Seeds\". The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Bayer Cropscience Limited has vide its letter inter-alia stated, \"The Company will not comment on market rumours.\" </td></tr></table>",
      "source": "NSE",
      "caption": "News Verification",
      "datetime": "09-Oct-2013"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Bayer CropScience Ltd has declared <strong>900%</strong> dividend, ex-date: 14 Nov 25",
          "dt": "2025-11-14",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Bayer CropSci. Sees Revision in Market Evaluation Amid Challenging Financial Trends

2025-11-27 10:06:18

Bayer CropSci., a small-cap player in the Pesticides & Agrochemicals sector, has experienced a revision in its market evaluation reflecting shifts in its financial and technical outlook. This adjustment follows a period marked by subdued growth and valuation concerns, prompting a reassessment of the company’s standing within its industry.

Why is Bayer CropSci. falling/rising?

2025-11-11 22:56:39

As of 11-Nov, Bayer CropScience Ltd is experiencing a decline in its stock price, currently at Rs 4,506.85, which reflects a decrease of 131.1 points or 2.83%. The stock has underperformed its sector by 2.4% today, touching an intraday low of Rs 4,490, which is a drop of 3.19%. Over the past week, the stock has seen a return of -6.81%, and its performance over the last month is also negative at -9.92%. Despite a rise in investor participation, with delivery volume increasing by 90.59% against the 5-day average, the stock is trading below all key moving averages, indicating a bearish trend. Additionally, the company has shown poor long-term growth, with operating profit declining at an annual rate of -3.22% over the last five years, and recent financial results have been flat, contributing to the negative sentiment surrounding the stock. In the broader market context, Bayer CropScience's performance contras...

How has been the historical performance of Bayer CropSci.?

2025-11-09 22:41:31

Answer: The historical performance of Bayer CropSci. shows a trend of increasing net sales and operating income over the years, with net sales reaching 5,473.40 Cr in March 2025, up from 5,106.20 Cr in March 2024 and 5,139.70 Cr in March 2023. However, operating profit (PBDIT) has seen a decline from 1,035.00 Cr in March 2024 to 809.30 Cr in March 2025. Profit before tax also decreased to 707.40 Cr in March 2025 from 941.40 Cr in March 2024, while profit after tax fell to 568.00 Cr from 740.50 Cr in the same period. The company's total assets increased to 5,236.20 Cr in March 2025, compared to 4,597.10 Cr in March 2024, indicating growth in the asset base. Total liabilities also rose to 5,236.20 Cr from 4,597.10 Cr, reflecting an increase in financial obligations. Cash flow from operating activities decreased significantly to 262.00 Cr in March 2025 from 951.00 Cr in March 2024, contributing to a net cash o...

Are Bayer CropSci. latest results good or bad?

2025-11-08 19:19:58

Bayer CropScience's latest financial results for Q2 FY26 highlight significant operational trends, particularly influenced by the seasonal nature of the agrochemicals business. The company reported net sales of ₹1,914.60 crores, reflecting a substantial sequential increase of 82.97% from the previous quarter, driven by heightened demand during the kharif sowing season. Year-on-year, revenue growth stood at 17.36%, indicating resilience in maintaining market share amidst competitive pressures. Net profit for the same quarter reached ₹278.70 crores, which is a notable increase of 94.50% quarter-on-quarter and 9.64% year-on-year. However, despite these positive profit figures, the operating margin experienced compression, standing at 18.20%. This represents a sequential improvement but a decline compared to the previous year, suggesting challenges in maintaining profitability amidst rising costs or competitiv...

Bayer CropScience Q2 FY26: Strong Quarter Masks Underlying Margin Pressure

2025-11-07 20:02:48

Bayer CropScience Ltd., a prominent player in India's pesticides and agrochemicals sector, reported a net profit of ₹278.70 crores for Q2 FY26 ended June 2025, marking a sequential surge of 94.50% from the preceding quarter's ₹143.30 crores. On a year-on-year basis, the company posted a 9.64% increase from ₹254.20 crores in Q2 FY25. Despite these headline gains, the stock has faced significant headwinds, plunging 30.80% over the past year and currently trading at ₹4,604.15 with a market capitalisation of ₹21,078 crores. The results reveal a company navigating seasonal volatility whilst grappling with margin compression that has persisted across multiple quarters.

Why is Bayer CropSci. falling/rising?

2025-11-06 22:45:25

As of 06-Nov, Bayer CropScience Ltd's stock price is currently at Rs 4,754.70, reflecting a decline of Rs 81.4 or 1.68%. The stock has been underperforming, having fallen consecutively for the last four days, resulting in a total decrease of 3.3% over the past week. It has also touched an intraday low of Rs 4,730, which represents a 2.19% drop. In terms of performance against benchmarks, Bayer has seen a significant decline, with a year-to-date return of -14.39% and a one-year return of -28.33%, both of which are considerably worse than the Sensex's positive returns. The stock is trading below all its moving averages, indicating a bearish trend, and there has been a decrease in investor participation, with delivery volume falling by 4.65% compared to the five-day average. In the broader market context, Bayer's short-term performance is notably worse than the Sensex, which has seen a decline of only 1.30% o...

Is Bayer CropSci. overvalued or undervalued?

2025-10-20 08:06:34

As of 17 October 2025, Bayer CropScience's valuation grade has moved from very expensive to expensive, indicating a slight improvement but still reflecting a high valuation. The company is currently considered overvalued. Key ratios include a PE ratio of 38.24, an EV to EBITDA of 30.04, and a Price to Book Value of 7.95, all of which suggest that the stock is trading at a premium compared to its earnings and book value. In comparison to its peers, Bayer CropScience's PE ratio is higher than UPL's 37.91 and BASF India's 47.93, which are both classified as attractive. The PEG ratio stands at 0.00, indicating no growth expectations factored into the price, which is concerning. Recent stock performance shows that Bayer has underperformed against the Sensex, with a year-to-date return of -9.24% compared to the Sensex's 7.44%, reinforcing the notion that the stock may not be a favorable investment at its current...

Is Bayer CropSci. overvalued or undervalued?

2025-10-19 08:06:31

As of 17 October 2025, the valuation grade for Bayer CropSci. has moved from very expensive to expensive. The company is currently considered overvalued based on its high valuation ratios, including a PE ratio of 38.24, an EV to EBITDA of 30.04, and a Price to Book Value of 7.95. Compared to peers, Bayer's valuation appears less attractive; for instance, UPL has a PE ratio of 37.91 and an EV to EBITDA of 9.14, while BASF India shows a PE of 47.93 with a lower EV to EBITDA of 28.64. Despite the company's strong ROCE of 48.74% and ROE of 20.79%, the high valuation ratios suggest that the stock may not provide sufficient upside potential. Additionally, Bayer CropSci. has underperformed against the Sensex, with a year-to-date return of -9.24% compared to the Sensex's 7.44%. This performance further supports the view that the stock is overvalued in its current market context....

Is Bayer CropSci. overvalued or undervalued?

2025-10-18 08:06:02

As of 17 October 2025, Bayer CropScience has moved from a valuation grade of very expensive to expensive. The company is currently considered overvalued based on its key financial metrics. The PE ratio stands at 38.24, while the EV to EBITDA ratio is 30.04, and the Price to Book Value is 7.95, all indicating a premium valuation compared to its peers. In comparison to its industry peers, Bayer CropScience's valuation appears high, especially when looking at UPL with a PE ratio of 37.91 and BASF India at 47.93. Additionally, the PEG ratio for Bayer is notably low at 0.00, suggesting that growth expectations may not justify the current price. Recent performance has also been underwhelming, with a year-to-date return of -9.24%, significantly lagging behind the Sensex's 7.44% return....

View All News